Innovations in the treatment and management of drug-resistant tuberculosis

This 7-day advanced course for TB clinicians is designed to integrate the most recent DR-TB guidelines, recommendations and research evidence on clinical and programmatic management of DR-TB with intensive fieldwork - interactive case analysis, study visits, group discussions and presentations.

TIME, language & logistics

In 2023 this course will be organized:

  • from 19 to 26 April 2023 (7 working days, including Saturday 22 April), Russian language- fully booked
  • from 16 to 23 of August 2023 (7 working days, including Saturday, 19 August), Russian language - registration is available! 
  • This course for the English-speaking audience will be organized in the 4th quarter of 2023 and the announcement will be available soon on our website! 
  • WHO CC Latvia ensures full logistic support to participants - including accommodation, local transfers, catering, and visa support.

VENUE

WHO CC Latvia, Tuberculosis and Lung Diseases Center, Riga East University hospital, Upeslejas, Ropazu district, LV-2118, LATVIA. The program covers field visits to the  TB facilities of the TB and Lung Diseases Center of Riga East University Hospital (e.g. DR-TB department, National TB Reference Laboratory, and TB Outpatient department), as well as the study visits to the local NGO`s/social/healthcare organizations providing services to the TB patients.

FACULTY

  • The faculty of WHO CC Latvia involves more than 20 experts, clinicians, scientists, researchers, nurses, and other public health sector staff engaged in TB care.
  • In addition, WHO CC Latvia regularly cooperates with international organizations and projects to engage the international experts from the field and provide high-level, evidence-based up-to-date training.
Exchange of experience course to scale up the competencies and knowledge of TB specialists in the clinical management of DR-TB in line with the current European Regional TB Action Plan as well as the novel approaches and evidence in programmatic management of drug-resistant TB.

The content of the course:

  • WHO Global strategies and targets for TB prevention, treatment and control.
  • Epidemiology of TB. Social determinants and control of TB. TB, M/XDR-TB and TB/HIV globally and in the WHO European Region.
  • Rapid tests for diagnosis of TB and DR-TB. Diagnostic algorithms.
  • Interpretation of genotypic drug-susceptibility results (including WGS).
  • Risk of development, pathogenesis, diagnosis, and treatment of M.tuberculosis infection.
  • Treatment of Isoniazid - sustainable TB. 
  • Drugs used for the treatment of TB and TBI.
  • Consolidated guidelines for the treatment of RR-TB.
  • DR-TB regimen selection and design.
  • Management of D/XDR-TB in special situations.
  • Treatment and management of drug-susceptible and drug-resistant resistant tuberculosis in children.
  • TB diagnosis and treatment for HIV co-infected patients.
  • Chronic viral hepatitis C: Treatment possibilities for both diseases at once.
  • Surgical treatment of pulmonary TB and M/XDR-TB.
  • Management of adverse events in DR/RR-TB treatment.
  • Pharmacovigilance. aDSM.
  • Monitoring of the treatment effectiveness.
  • Monitoring and evaluation. Treatment outcome definitions.
  • The role of operational research in the TB programs.
  • Nontuberculous Mycobacterial Pulmonary Disease.
  • Extrapulmonary tuberculosis.
  • Principles of out-patient treatment, its possibilities.
  • DOT vs VOT.
  • Systematic screening of contacts and high-risk groups.
  • Developing models of integrated and person-centered care for DR-TB patients.
  • The role of operational research in the TB programs.
  • Effective Communication for healthcare workers working with TB.
  • Systematic screening for TB.
  • Fundamentals of infection control for TB. FAST Strategy.
  • Management of failures and palliative care.
  • Post - TB Lung disease.

To apply for this course, please fill in the course registration form below:























Fee, the deadline for registration and visa:

  • The registration deadline for the course 16-23 of August is 19 June 2023. Please note that we can accept a limited number of participants for this course. 
  • The tuition fee for this course is 1600 EUR per participant, covering: training materials, field visits, lunches and coffee breaks on working days/working hours, local transfers, and visa invitation support.
  • In addition to the tuition fee participants should cover their international flight, hotel accommodation, visa, and other personal expenses. 
  • Please note, that payments are possible only by bank transfers based on the invoice issued by the Latvian Society against TB or a contract with the collaborating institution. 
  • WHO CC Latvia will arrange the accommodation for all guests at 4* hotel in Riga city center for a special group price (single /standard room with breakfasts 75 EUR per night/per person). You will receive detailed information after registration for the course. 
  • Please check if you need a visa for travel to Latvia, WHO CC Latvia will provide support in visa invitation arrangements.  

For group reservations or any questions, you are welcome to contact the WHO CC Latvia office:
  • Course director Dr. Liga Kuksa, ligakuksa@gmail.com;
  • Course coordinator Liga Rusmane, liga.rusmane@gmail.com; t. +371 29774267